EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.52) per share which met the analyst consensus estimate. This is a 23.81 percent decrease over losses of $(0.42) per share from the same period last year. The company reported quarterly sales of $11.56 million which beat the analyst consensus estimate of $10.87 million by 6.39 percent. This is a 28.31 percent increase over sales of $9.01 million the same period last year.
EyePoint Pharmaceuticals Q2 EPS $(0.52), Inline, Sales $11.56M Beat $10.87M Estimate
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported quarterly losses of $(0.52) per share which met the analyst consensus estimate. This is a 23.81 percent decrease over losses of $(0.42) per share from the same period last
Related Posts
Emerald Expositions Q4 EPS $0.06 Up From $(0.24) YoY, Sales $93.60M Up From $41.10M YoY
Emerald Expositions (NYSE:EEX) reported quarterly earnings of $0.06 per share. This is a 125 percent increase over losses of $(0.24) per share from the same period last year. The company reported $93.60 million in sales
Salesforce Options Traders Betting On Stock Hitting New 2023 Highs After Earnings
Salesforce, Inc. (NYSE: CRM) shares surged to a new all-time high on Tuesday ahead of the company’s earnings report.
Supply Chain Problems May Disrupt Air Travel In Summer 2023: Report
This year, "very frustrating" supply chain issues will disrupt air travel, according to the director general of the International Air Transport Association.